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Molecular  diagnostic  measurements  are  currently  underpinned  by  the  polymerase  chain  reaction  (PCR).
There are  also  a number  of  alternative  nucleic  acid ampliﬁcation  technologies,  which  unlike  PCR,  work  at
a single  temperature.  These  ‘isothermal’  methods,  reportedly  offer  potential  advantages  over  PCR  such  as
simplicity,  speed  and  resistance  to  inhibitors  and  could  also  be used  for  quantitative  molecular  analysis.
However  there  are  currently  limited  mechanisms  to evaluate  their  quantitative  performance,  which
would  assist  assay  development  and  study  comparisons.  This  study  uses  a  sexually  transmitted  infectioniagnostics
sothermal nucleic acid ampliﬁcation
uantitative LAMP
uantitative real time PCR
tandardisation
diagnostic  model  in  combination  with  an adapted  metric  termed  isothermal  doubling  time  (IDT),  akin
to PCR  efﬁciency,  to compare  quantitative  PCR  and quantitative  loop-mediated  isothermal  ampliﬁcation
(qLAMP)  assays,  and  to quantify  the  impact  of  matrix  interference.  The  performance  metric  described  here
facilitates  the  comparison  of qLAMP  assays  that could  assist  assay  development  and  validation  activities.
© 2014  The  Authors.  Published  by  Elsevier  GmbH.  This  is  an  open  access  article  under  the  CC. Introduction
The use of molecular approaches for clinical diagnosis has
ncreased over the past 30 years since the development of PCR [1]
esulting in a wide variety of diagnostic applications [2–4]. Alter-
ative nucleic acid ampliﬁcation (NAA) technologies, reviewed by
raw and colleagues [5–7], utilising isothermal conditions offer
 range of potential advantages over PCR, including speed and
implicity, and lend themselves to near patient and point of care
iagnostic testing [8,9]. Loop-mediated isothermal ampliﬁcation
LAMP) [10] is an example of an isothermal NAA technology that is
ypically faster than PCR [11–13] and reportedly less susceptible to
ommon biological inhibitors [14–17]. LAMP has been successfully
Abbreviations: Cq, quantiﬁcation cycle; IDT, isothermal doubling time; MIQE,
inimum information for the publication of quantitative real-time PCR exper-
ments; NAA, nucleic acid ampliﬁcation; qLAMP, quantitative loop-mediated
mpliﬁcation; qPCR, quantitative real-time polymerase chain reaction; td, doubling
ime; Tt , threshold time.
∗ Corresponding author at: Molecular and Cell Biology, LGC, Queens Road, Ted-
ington, UK.
E-mail address: gavin.nixon@lgcgroup.com (G.J. Nixon).
ttp://dx.doi.org/10.1016/j.bdq.2014.11.001
214-7535/© 2014 The Authors. Published by Elsevier GmbH. This is an open acces
y-nc-nd/3.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
utilised in the development of a wide range of diagnostic assays
[18–20].
The application of LAMP to measure template abundance, orig-
inally established by real time quantitative PCR (qPCR), has been
explored by a variety of laboratories [17,20–26]. However, real time
quantitative LAMP (qLAMP) is a relatively immature technology
compared with qPCR and demonstrates poor quantitation capa-
bilities below 1000 target copies [22,23,26]. Threshold time (Tt)
[26] is a real-time quantitative LAMP measurement analogous to
quantiﬁcation cycle (Cq) [27] and is central to quantifying template
abundance using qLAMP. While Tt, allows quantiﬁcation to be per-
formed there is currently no agreed method for expressing assay
performance or deﬁning the magnitude of a difference between
two results when conducting qLAMP; a role that ‘PCR efﬁciency’ has
provided since the development of qPCR. Metrics for assay perfor-
mance are essential to enable assay optimisation, evaluation of the
impact of matrices [28–31] and to facilitate laboratory comparison.
An isothermal performance metric, analogous to PCR efﬁciency,
has been proposed for real-time helicase dependent ampliﬁcation
(HDA) [32] reactions by Goldmeyer and colleagues [33], termed
doubling time (td) and calculated by comparing the time required
by different starting quantities of template to reach a uniform
s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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hreshold (2-point approach). We  discuss the application of a more
omprehensive metric termed isothermal doubling time (IDT) that
tilised a standard curve-based approach to provide an equation
based on the slope of the Tt against concentration) to deﬁne the
agnitude of a difference in results and estimate assay perfor-
ance which also beneﬁts from evaluating the linear dynamic
ange.
Effective mechanisms for comparing the performance of NAA
echnologies such as qLAMP to that of established PCR-based
pproaches is central to the uptake of these technologies and
stablishing conﬁdence in their diagnostic potential. This paper
escribes a methodology for assessing quantitative isothermal
ucleic acid ampliﬁcation performance that, similar to PCR efﬁ-
iency for qPCR [34], can assign a relative value to any qLAMP assay.
e investigate the application of this metric to target pathogens
nd assess the impact of inhibition on assay performance.
. Materials and methods
.1. Artiﬁcial urine matrices
A panel of artiﬁcial urine matrices (Table S1) were developed
rom published work [35] that contained varying levels of urea con-
entration (500 or 1000 mM urea) which is a known PCR inhibitor
29]. For investigations into matrix impact, reactions were supple-
ented with 10% (v/v) of the respective artiﬁcial matrix.
.2. Cultured DNA extracts
Chlamydia trachomatis, serovar E (ATCC VR-348BD) genomic
NA containing co-puriﬁed cryptic plasmid DNA and Mycoplasma
enitalium G37 (ATCC 33530D) gDNA (LGC Standards, Tedding-
on, United Kingdom) were used as genomic templates. Ten-fold
erial dilutions (∼5 × 104 to ∼50 copies per reaction) of each DNA
emplate (spectrophotometrically quantiﬁed) were prepared in
.25 ng l−1 sonicated salmon sperm DNA carrier (GE Healthcare,
halfont St Giles, United Kingdom).
.3. Clinical puriﬁed DNA samplesAll initial clinical sample puriﬁcation and molecular screening
ctivities were performed at University College London Hospitals
UCLH), London, United Kingdom. 24 pre-screened DNA samples
GAAATCCCTCGTGATATAACCTAtccgtaaaatgtcctgat 
gtatttttttatataaacatgaaaactcgttccgaaATAGA 
AGCTCTGATATTTGAAGACTCTACTGAGTATATTCTGAGGC
ACATATTCATAGTATTTAAATACTTAAAAGACAATGGATTA 
CGTCGTATCAAAGATATGGACAAATCGTATCTCGGGTTAAT
TTCTCATACGGTTTTCCTCGATGATTTGAGCGTGTGTAGCG
1081 bp
I Crypc qPCR Amplicon
Crypc qLAMP Amplicon
GCTTTATATGATATTAACTTAGCAAAAATGGAAAACCCCTC
tccttttaaaggctttggtttaactggtaatgcccctaatg 
TTCAATCCCCCCATTCCCCCAACCTCTATTTTCTGTTACTA
CAAGTAGTCAAAGAGAGTTTGGAAGTGGAAGCAACCCAATC 
161 bp
I MgPa qLAMP Ampl
(a)
(a)
ig. 1. Target sequences with corresponding amplicon regions for qLAMP (shaded sequ
NA  for growth within mammalian cells (GenBank Acc#X07547) 1081–1560 bp target re
GenBank Acc#X91072) 161–480 bp target region for qPCR and qLAMP assay. and Quantiﬁcation 2 (2014) 4–10 5
with deﬁned M.  genitalium and C. trachomatis content (mix of
positives and negatives) were provided blind by UCLH for com-
parative analysis at the approval of the Chair of the Camden and
Islington Community Research Ethics Committee.
C. trachomatis testing was  performed as part of a routine clini-
cal diagnostic protocol. Testing process overview: cervical swabs,
self-taken vaginal swabs or urine samples were collected and
transported in 3 or 4 ml  of APTIMA transport medium (Gen-Probe
Incorporated, San Diego, USA) mixed with urine 1:1 (v/v) for rou-
tine C. trachomatis testing. The test sample (400 l) was analysed
using the APTIMA CT assay on the TIGRIS® platform (Gen-Probe
Incorporated, San Diego, USA).
For initial M.  genitalium analysis, 200 l samples were taken
from materials previously tested for C. trachomatis, puriﬁed using
a BioRobot 9604 automated workstation using the QIAamp® Virus
BioRobot® 9604 Kit (QIAGEN, Hilden, Germany) and eluted in 50 l
elution buffer (QIAGEN, Hilden, Germany). The eluate (7 l, equiv-
alent to 28 l of the original volume) was analysed by a qPCR assay
adapted from Jensen et al. [36] incorporating a mouse CMV (mCMV)
internal control system [37].
2.4. qPCR assay design and conditions
qPCR assays were designed to detect the C. trachomatis
cryptic plasmid (GenBank Accession #X07547), and the M.
genitalium partially sequenced MgPa gene (GenBank Accession
#X91072) from strain M2300. The real-time PCR assays (Fig. 1,
Table 1) were designed using Primer Express 2.0 (Life Technolo-
gies Ltd, Paisley, UK) using default design parameters and the
sequences screened for homology using the BLASTn algorithm
(http://blast.ncbi.nlm.nih.gov/) that revealed no database align-
ments likely to cause cross reactivity, other than the region of
interest. HPLC puriﬁed oligonucleotide primers and FAM/TAMRA
hydrolysis probes were synthesised by Euroﬁns Genomics (Ebers-
berg, Germany). HPLC puriﬁed FAM/NFQ TaqMan® MGB  probes
were provided by Life Technologies Ltd (Paisley, UK). Preliminary
primer/probe optimisation was  conducted to determine optimal
PCR conditions.
The qPCR reactions (20 l volume) were performed compris-
ing 1× TaqMan® Universal PCR Master Mix  (Life Technologies
Ltd, Paisley, UK), 900 nM forward and reverse primers, 200 nM
6-carboxyﬂuorescein (6-FAM) labelled hydrolysis probe, sample
template (10 fold dilution series from ∼5 × 104 to ∼50 copies)
tagtgaaataatcaggttgttaacaggatagcacgctcg
AAATCGCATGCAAGATATCGAGTATGCGTTGTTAGGTAA
AGCTTGCTAATTATGAGTTTAAGTGTTCTCATCATAAA A
CCTATAACTGTAGACTCGGCTTGGGAAGAGCTTTTGCGG
GTTGCATGATGCTTTATCAAATGACAAGCTTAGATCCGT
CTGAAGAAAATTTGAGTAATTTCATTTTCCGCTCGTTT A
I
1560 bp
AACGGTGCAAAGGGGTTTAAATggcgagcctatctttga
attggaatgagatcaaaggtaaagttCCAGTAGAAGTA G
GTGCCTAAGGTGGCATTAGAGTATCACAACCTGAATAAC
ATCCTTCAACCCCACCCAAAGGTTGAAGAGTGGGAGTCC
I
480 bp
MgPa qPCR Ampl iconicon
MgPa qLAMP Amplicon
ence) and qPCR assays (underlined sequence). (a) Chlamydia trachomatis plasmid
gion for qPCR and qLAMP assay. (b) M.  genitalium partial MgPa gene (strain M2300)
6 G.J. Nixon et al. / Biomolecular Detection and Quantiﬁcation 2 (2014) 4–10
Table 1
NAA assays – primer and probe details.
Type Target Sequence names Sequence details
qPCR C. trachomatis CRYPTIC MGB  FWD1 5′-TCCGTAAAATGTCCTGATTAGTGAAAT-3′
Cryptic plasmid CRYPTIC MGB  REV1 5′-TTCGGAACGAGTTTTCATGTTTATAT-3′
(#X07547) CRYPTIC MGB  PROBE1 5′-FAM-AGGATAGCACGCTCGGTA-MGB-NFQ-3′
M.  genitalium MGPA TM FWD2 5′-GGCGAGCCTATCTTTGATCCT-3′
MgPa gene MGPA TM REV2 5′-AACTTTACCTTTGATCTCATTCCAATC-3′
(#X91072) MGPA TM PROBE2 5′-FAM-AAGGCTTTGGTTTAACTGGTAATGCCCCT-TAMRA-3′
qLAMP C. trachomatis Cryptic F3(3) 5′-ACTTAAAAGACAATGGATTACCT-3′
Cryptic plasmid Cryptic B3(3) 5′-AATTACTCAAATTTTCTTCAGCG-3′
(#X07547) Cryptic FIP(3) 5′-CCGAGATACGATTTGTCCATATCTTATAACTGTAGACTCGGCTTG-3′
Cryptic BIP(3) 5′-TGTTGCATGATGCTTTATCAAATGACACACGCTCAAATCATCGA-3′
Cryptic LF(3) 5′-CGCCGCAAAAGCTCTTCC-3′
Cryptic LB(3) 5′-CTTAGATCCGTTTCTCATACGGTTT-3′
M.  genitalium PA F3(5) 5′-GAAAACCCCTCAACGGTG-3′
MgPa gene PA B3(5) 5′-CTTGGTTATTCAGGTTGTGAT-3′
(#X91072) PA FIP(5) 5′-AGGGGCATTACCAGTTAAACCAAAAAAGGGGTTTAAATGGCGA-3′
PA BIP(5) 5′-ATGAGATCAAAGGTAAAGTTCCAGTCACTAGTAACAGAAAATAGAGGTT-3′
PA LF(5) 5′-GCCTTTAAAAGGATCAAAGATAGGC-3′
PA BF(5) 5′-AGAAGTAGTTCAATCCCCCCAT-3′
#
a
A
p
7
l
f
a
v
l
c
a
d
2
C
g
d
t
a
c
(
C
e
s
a
p
U
d
t
p
p
A
n
c
i
p
(
s
i
Gen-Probe assay (400 l). To simulate how the respective technolo- denotes GenBank accession number.
nd, where appropriate, 10% (v/v) synthetic matrices (Table S1).
ll oligonucleotide primers and hydrolysis probes were HPLC
uriﬁed. Reactions were performed using the Applied Biosystems
900HT Fast Real-Time PCR System (Life Technologies Ltd, Pais-
ey, UK) and standard cycling conditions: 50 ◦C for 2 min, 95 ◦C
or 10 min, 50 cycles at 95 ◦C for 15 s and 60 ◦C for 1 min. Data
nalysis was performed using Sequence Detection Software (SDS)
ersion 2.4 (Life Technologies Ltd, Paisley, UK) with manual base-
ine/threshold settings to estimate quantiﬁcation cycle (Cq). Water
ontrol assays were included in which template was  omitted to
ssess the presence of contamination, all water control assays pro-
uced no detectable Cq signal.
.5. qLAMP assay design and conditions
qLAMP assays were designed to detect a similar region of the
. trachomatis cryptic plasmid and partial M.  genitalium MgPa
ene as that designed for the qPCR assays, however, due to
esign constraints exactly the same genetic region could not be
argeted for the cryptic plasmid target (Fig. 1 for qLAMP/qPCR
mplicon comparisons). The qLAMP assays (Fig. 1, Table 1)
omprising 4 core primers (F3/B3/FIP/BIP) and 2 loop primers
LF/LB) were designed using PrimerExplorer V4 (Eiken Chemical
o., Ltd., Tokyo, Japan) online software (http://primerexplorer.jp/
lamp4.0.0/index.html) using default design parameters. The
equences were screened for homology using the same approach
s for qPCR primers.
The qLAMP reactions (20 l volume) were performed com-
rising 1× isothermal master mix  (OptiGene Limited, Horsham,
nited Kingdom) containing proprietary intercalating ﬂuorescent
ye, 200 nM F3/B3/LF/LB primers, 800 nM FIP/BIP primers, sample
emplate (∼5 × 104 to ∼50 copies per reaction) and, where appro-
riate, 10% (v/v) synthetic matrices (Table S1). All oligonucleotide
rimers were HPLC puriﬁed. Reactions were performed using the
pplied Biosystems 7900HT Fast Real-Time PCR System (Life Tech-
ologies Ltd, Paisley, UK) under the following thermal cycling
onditions: 65 ◦C/45 min  (60 × 45 s cycles), and ﬂuorescence mon-
tored over the SYBR Green I spectral region. Data analysis was
erformed using Sequence Detection Software (SDS) version 2.4
Life Technologies Ltd, Paisley, UK) with manual baseline/threshold
ettings to estimate Threshold Time (Tt). Water control assays were
ncluded in which template was omitted to assess the presence ofcontamination, all water control assays produced no detectable Tt
signal.
2.6. Comparison studies
2.6.1. Matrix evaluation
Experiments were conducted to compare the performance of
speciﬁc qLAMP assays with comparable qPCR assays in the pres-
ence of two different matrices (artiﬁcial urine matrix containing
50 or 100 mM urea ﬁnal concentration, Table S1). Three indepen-
dent experiments were performed per assay/NAA technology and
each reaction performed in triplicate.
2.6.2. qLAMP and qPCR performance assessment
Standard curve analysis (log10 transformed input copy number
plotted against Cq or Tt) was  performed to evaluate the perfor-
mance of the qPCR and qLAMP assays and enable calculation of PCR
efﬁciencies [34] and isothermal doubling times (IDT = −0.301 m,
whereby 0.301 corresponds on the base 10 logarithmic scale to a
change in concentration of a factor of 2 and m = slope). The use of
real time PCR instrument to undertake isothermal studies neces-
sitates the conversion of the qPCR instrument output (Cq) to Tt
through the application of a time multiplier (cycle time), which
in this experiment consisted of 45s cycles.
2.6.3. Clinical comparison
The 24 pre-screened clinical DNA samples (pathogen status
determined by UCLH) comprising 18 positives (7× M.  genitalium,
7× C. trachomatis and 2× C. trachomatis and M. genitalium) and 8
negatives, were used to investigate the C. trachomatis and M. gen-
italium assays using both NAA platforms on real clinical samples.
Due to sample limitations single replicates of each clinical sam-
ple, comprising 1 l volumes, were interrogated using appropriate
qPCR or qLAMP-based assays. This corresponded to 4 l of the orig-
inal sample volume and was  less than the initial sample analysed
by UCLH with the M. genitalium qPCR (28 l) or the C. trachomatisgies performed with clinical extracts in the presence of inhibition, a
repeat measurement was performed in which artiﬁcial urine matrix
to include 100 mM urea (ﬁnal reaction concentration) was  also
added.
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eactions per three experiments when threshold set at the same respective ﬂuoresc
. Results
.1. Establishing baseline performance
Standard curve-based analyses of the C. trachomatis and M. gen-
talium qPCR assays (Fig. 2a and b, Table S2a) show that the assays
chieved good linearity and precision (mean R2 measurements of
.00), displayed good levels of PCR sensitivity (Fig. 3a and b) and are
apable of repeatedly detecting ∼5 copies of target material under
xperimental conditions.
Comparable standard curve-based analyses of the qLAMP assays
Fig. 2c and d, Table S2b) displayed a reduced dynamic range as
ompared to the qPCR assays which was characterised by a loss of
inear response below the 1000 target copies input level. Variable
2 measurements (0.82 and 0.97) and higher levels of error (Table
3) for both assays highlight the lower levels of precision asso-
iated with qLAMP compared to qPCR. Both assays display good
ower levels of detection sensitivity (Fig. 3c and d) and are capa-
le of detecting 5 theoretical copies of target material under ideal
onditions, although this was not quantitative below 1000 copies.
.2. Assessing the impact of urea containing matrices
We  investigated the impact of artiﬁcial matrices containing two
oncentrations of urea, a known PCR inhibitor [29] and found that
rea had a differential impact upon the performance of both NAA
echnologies typiﬁed by a right shift in Cq/Tt (Fig. 2). 100 mM urea
ffects the cryptic plasmid qPCR assay by causing a positive shift in
q for the 50,000 copies sample from 23.50 ± 0.09 to 26.89 ±0.83 Cq
hile a comparable qLAMP reaction demonstrates a Tt shift from
87.24 ± 5.14 to 726.00 ± 12.95 s. While the presence of inhibitors
roduced an appreciable delay in qLAMP ampliﬁcation, both assays
ere able to routinely detect ∼5 copies of template regardless of
he inhibition levels (Fig. 3c and d). In comparison, the qPCR assaysformance. Plots displaying mean Cq [(a) & (b)] and Tt [(c) & (d)] from three separate
 Error bars illustrate standard deviations.
were only appreciably affected by the presence of 100 mM urea
which reduces the detection capabilities of both assays to above
500 template copies (Fig. 3a and b).
3.3. Comparing NAA assay performance
Initial evaluation work demonstrated that the NAA technolo-
gies displayed different performance characteristics and responses
to matrices. PCR efﬁciency and IDT metrics were used to compare
intra-assay performance and investigate the impact of an inhibitor
on qLAMP and qPCR assay performance. The PCR efﬁciency and IDT
data correlates well with the initial matrix assessment work uti-
lising performance metrics as characterised by increased Ct/Tt and
lower PCR efﬁciency/higher IDT in the presence of inhibitors. PCR
efﬁciency and IDT data suggested that the qPCR assays (Fig. 4a)
were less affected by the presence of 50 mM urea than the compa-
rable qLAMP assays (Fig. 4b). Reductions in PCR efﬁciencies (below
50%) were only observed with the 100 mM urea matrix samples.
Matrices containing 100 mM urea had a pronounced impact on
the performance of both qPCR assays characterised by a loss of
assay sensitivity (Fig. 3a and b), increased Cq and reduced efﬁciency
(Fig. 4a).
In  comparison, qLAMP assays show a minimum ∼1.5× increase
in IDT that is unaffected by urea concentration (Fig. 4b) and sug-
gests that urea is not responsible for the observed impact on assay
performance.
3.4. Clinical evaluation
The performance of the two  NAA technologies was further eval-
uated using the M. genitalium and C. trachomatis qLAMP/qPCR
assays with clinical samples. 24 Clinical DNA extracts with deﬁned
M. genitalium and C. trachomatis status were evaluated by all assays
in the presence/absence of 100 mM urea. A detailed assessment of
8 G.J. Nixon et al. / Biomolecular Detection and Quantiﬁcation 2 (2014) 4–10
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sig. 3. Comparative analysis of qPCR and qLAMP assay ampliﬁcation success. Plots d
eparate reactions per 3 experiments (n = 9).
iagnostic efﬁcacy for either technology could not be performed
ue to sample limitations, however this study clearly demonstrated
hat both qPCR and qLAMP were able to detect their respective
athogen targets from clinical sample extracts. We  demonstrated
hat the MgPa qPCR assay was more sensitive than the corre-
ponding qLAMP assay (Table 2a) while the cryptic plasmid qLAMP
ssay demonstrated comparable performance to the cryptic plas-
id  qPCR assay (Table 2b). With the exception of one sample, the
LAMP assay’s detection response (Table 2) was unaffected by the
resence of the artiﬁcial matrices, while both qPCR assays were
lways inhibited when 100 mM urea matrix was present.
. DiscussionCurrent molecular diagnostic standardisation activities are
riven by international organisations such as the Laboratory Stan-
ards Institute (CLSI) [38] and user driven initiatives such as
Minimum Information for Publication of Quantitative Real-Time
(a) 
Cryptic A
MgPa As
             qPCR Assay PCR Eff iciencies
Refere nce 50  mM  Ur ea 100 mM  Ure a
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           Sample Type
%
 P
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ig. 4. Methodologies to compare general assay performance. (a) Percentage PCR efﬁci
eparate experiments, 3 technical replicates). Error bars denote inter-experimental standying qPCR [(a) & (b)] and qLAMP [(c) & (d)] successful ampliﬁcation data from three
PCR Experiments (MIQE) Guidelines’ which aim to improve mea-
surement comparability and traceability [27]. Metrics such as PCR
efﬁciency, aid qPCR measurement and ultimately reproducibil-
ity but comparable tools available to evaluate qLAMP, and other
isothermal assays, are limited. To this end, this study developed
a performance metric (IDT) and compared it to the application of
equivalent qPCR metrics.
Differences in performance were observed between the two
NAA technologies, with qPCR displaying better sensitivity and
quantitative precision when compared to qLAMP. However, the
qualitative potential of qLAMP was  not affected by the presence
of artiﬁcial urine-type matrices containing urea, which repre-
sents an inhibitor found in urine-based clinical samples/extracts.
In addition, this ﬁnding supports the applicability of LAMP to the
direct testing of clinical urine samples without the need for time-
consuming extraction steps [12,16].
While our ﬁndings support the general assumption that qual-
itative LAMP ampliﬁcation may  be less susceptible to inhibitors
(b)  
ssay
say
qLAMP Isother mal Doubling  
Times Comparison
Reference 50 mM Urea 100 mM Urea
0
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Samp le Type
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T 
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)
ency, (b) Isothermal Doubling Times. Plots displaying IDT or PCR efﬁciency (n = 3
ard deviations.
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Table  2
Clinical samples screening results. 24 clinical DNA extracts screened against a panel
of (a) Mycoplasma genitalium and (b) Chlamydia trachomatis qPCR and qLAMP assays
in the presence or absence of urine type artiﬁcial matrix containing 100 mM urea
(ﬁnal concentration). Negative samples not displayed (100% concordance with both
assays). Respective Cq and Tt (s) data displayed (rounded to nearest whole number),
‘ND’  denotes no detection and shaded regions highlight positive assay responses.
Sample qPCR (Cq) qLAMP (Tt)
Minus urine Plus urine Minus urine Plus urine
(a) Screening results for the Mycoplasma genitalium qPCR and qLAMP assays
1  38 ND ND ND
7  30 ND 796 1472
10 36 ND ND ND
12  38 ND ND ND
16  34 ND 922 2476
21  ND ND ND ND
28  31 ND 848 1486
29  40 ND ND ND
34  30 ND 683 1292
Total 8 0 4 4
(b)  Screening results for the Chlamydia trachomatis qPCR and qLAMP assays
5  ND ND 985 ND
6  ND ND ND ND
10  29 ND 694 1269
11  38 ND ND 1565
16  31 ND 910 1267
22  29 ND 642 1069
23  ND ND ND ND
24  32 ND 894 1316
26  20 ND 477 906
t
t
e
t
c
T
s
d
w
q
c
o
s
m
t
o
I
a
a
v
b
t
w
p
P
i
i
s
n
n
t
a29  ND ND ND ND
Total 6 0 6 6
han qPCR, as others have observed [14,39], we  have demonstrated
hat quantiﬁcation using qLAMP is susceptible to matrix interfer-
nce. Our data suggests that LAMP-based assays are susceptible
o alternative inhibitory processes than those observed for qPCR as
haracterised by an increase in Isothermal Doubling Time (IDT) and
t shift that is not dependent upon urea concentration.
These results support our previous ﬁndings [17] which demon-
trated that inhibitors can exhibit different levels of inhibition on
ifferent nucleic acid ampliﬁcation methods and Tani et al. [14]
ho observed that urea (up to 400 mM)  has little effect on the
uantitative performance of qLAMP, indicating that other matrix
omponents are responsible for the observed inhibitory effect. The
bserved gross change in IDT would affect any quantitative mea-
urements and require appropriate correction mechanisms such as
atched calibrator and test matrices.
Performance comparison was achievable through the applica-
ion of the commonly used PCR efﬁciency metric and our adaptation
f the doubling time (td) [33] approach that we  have termed
DT. IDT provides a mechanism by which a fold difference can be
ttributed to multiple target dilution points rather than two points
s utilised to calculate td. The standard curve-based approach pro-
ides an estimate of qLAMP assay performance that minimises
iases associated with dual-point estimations. PCR is only able
o perform a maximum of a doubling of all templates per cycle
hen it is at its optimum and thus PCR efﬁciency is reported as a
ercentage. qLAMP does not have the same cyclical constraint as
CR and thus IDT does not have a clearly deﬁned physical max-
mum.  IDT has the potential to be used for other quantitative
sothermal technologies as long as there is a log linear relation-
hip between Tt and concentration such as observed with real-time
ucleic acid sequence-based ampliﬁcation (NASBA) and recombi-
ase polymerase ampliﬁcation (RPA) approaches [40,41].
IDT also provides users with a common baseline measurement
o compare the performance of compatible isothermal NAA assays
nd support assay development activities such as optimisation or and Quantiﬁcation 2 (2014) 4–10 9
investigating the impact of inhibitors. Inhibition was demonstrated
to affect the qLAMP and qPCR reactions through an increase in Tt or
Cq respectively, as well as a reduction in PCR efﬁciency or increase
in IDT.
IDT can be estimated using standard curves, as performed here,
or to assess sample speciﬁc performance in the same way as qPCR
when performing relative quantiﬁcation [42]. This not only facili-
tates comparison between assays within the same laboratory, but
also between laboratories and enables reporting of a key assay
characteristic similar to qPCR efﬁciency; which is agreed to be an
important factor that should be stated when performing qPCR [27].
This study highlighted the reduced precision associated with
qLAMP when compared to qPCR (Table S3) and suggests further
work on assay components such as enzymes and buffer systems is
necessary to improve qLAMP performance. However, it should be
remembered that qPCR has beneﬁtted from over a decade of con-
tinuous development that contrasts with the relative immaturity
of the LAMP.
LAMP has the potential to complement existing qPCR based
techniques that are currently the gold standard within the molec-
ular diagnostics ﬁeld, but is limited by poor quantitation below
1000 target copies. This could be alleviated through the use of
approaches similar to digital PCR, subject to sensitivity issues aris-
ing from current assayable sample volume limitations [17], or
through improvements in LAMP chemistry, e.g. enzyme optimisa-
tion [43]. The metric proposed by this study provides a mechanism
that can facilitate such research and development work and ulti-
mately assist in the transfer of novel LAMP-based methods into
diagnostic tests.
5. Conclusion
We demonstrate the application of a performance metric com-
parable to PCR efﬁciency in the evaluation of qLAMP assays which
is potentially applicable to other isothermal NAA technologies. The
isothermal doubling time metric described here facilitates the com-
parison of qLAMP assays that could assist assay development and
validation activities within the developer and user communities.
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